Summary

KEY FINDINGS
The North America dry eye disease market is expected to grow at a CAGR of 5.12% during the forecast period of 2024 to 2032. The market was valued at $2283.72 million in 2032, reaching a projected revenue of $3604.57 million by 2032.
MARKET INSIGHTS
The rising geriatric population in North America is a significant factor contributing to the growing number of cases of dry eye diseases. Older individuals are more prone to conditions affecting tear production, leading to common dry eye disease symptoms such as dryness, burning, and blurred vision. Environmental factors and lifestyle changes, including increased screen time, are also contributing to the increasing prevalence of dry eye disease across all age groups.
REGIONAL ANALYSIS
The North America dry eye disease market growth analysis includes a detailed examination of the United States and Canada. Technological advancements in therapeutic and diagnostic products are facilitating more effective treatment for dry eye disease. New dry eye disease treatment drugs and products, including artificial tears and anti-inflammatory medications, are improving patient outcomes. Moreover, the demand for dry eye disease treatment devices is on the rise, as these devices help enhance tear production and alleviate symptoms. Innovations in eye drops and treatment technologies are addressing the need for more efficient and targeted solutions.
In the United States, a National Health and Wellness Survey reports that 6.8% of the adult population is affected by dry eye disease, with prevalence increasing with age and being higher in females compared to males. Further analysis from the 2017 National Health and Wellness Survey (NHWS) indicates that the gender disparity in dry eye disease prevalence widens as age increases. Consequently, healthcare professionals expect a rise in cases of dry eye syndrome among the aging population.
Additionally, product launches and innovations by major companies are poised to boost market opportunities. For example, in 2022, Bausch + Lomb presented data from a second pivotal Phase 3 trial for their investigational treatment, NOV03. This would be the first pharmaceutical therapy in the United States featuring a new mechanism of action specifically targeting the relief of dry eye symptoms related to Meibomian gland dysfunction.
SEGMENTATION ANALYSIS
The North America dry eye disease market segmentation includes type, product, dosage, and distribution channel. The type segment is further classified into OTC and prescription.
Over-the-counter (OTC) treatments, including artificial tears and lubricating eye drops, are widely used products by patients for quick relief from dry eye disease symptoms. Leading players in this segment include Johnson & Johnson, which provides a variety of eye care products aimed at addressing dry eye symptoms. Companies such as Alcon and Allergan PLC also play a significant role in the OTC segment with their range of treatments for dry eye disease.
While the demand for anti-inflammatory drugs and treatment devices continues to rise, one of the challenges facing the market is the underdiagnosis of dry eye disease. Many patients remain unaware of their condition or do not seek proper treatment. However, increasing awareness through educational initiatives and improved access to diagnostic tools are expected to boost diagnosis rates, allowing for more effective management of the disease.
COMPETITIVE INSIGHTS
Some of the key firms operating in the North America dry eye disease market are Novartis AG, Novaliq GmbH, Lumenis, Oasis Medical, etc.
Oasis Medical Inc, headquartered in Los Angeles, California, is a specialized manufacturer of surgical supplies, instruments, disposables, and eye care products. The company produces a wide range of products aimed at treating retinal diseases, dry eye disease, refractive errors, and cataracts. One of its flagship products, Oasis TEARS® PF PLUS Preservative-Free Lubricant Eye Drops, is designed to combat dry eye, offering viscoadaptive properties and strong adherence for effective relief.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON THE DRY EYE DISEASE MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. PROLONGED SCREEN EXPOSURE CAN TRIGGER SYMPTOMS OF DRY EYE
2.5.2. INDIVIDUALS OF ASIAN DESCENT ARE MORE SUSCEPTIBLE TO DEVELOPING DRY EYE DISEASE
2.5.3. AIR POLLUTION IS A SIGNIFICANT CONTRIBUTOR TO EYE-RELATED CONDITIONS
2.5.4. THE COVID-19 PANDEMIC HAS LED TO A SURGE IN DRY EYE DISEASE CASES
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. RISING INCIDENCE AND PREVALENCE OF DRY EYE AMONG VARIOUS AGE GROUPS
3.1.2. LAUNCH OF PIPELINE PRODUCTS FOR THE TREATMENT OF DRY EYE DISEASE
3.1.3. INTRODUCTION OF NEW DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS ASSOCIATED WITH TREATMENTS
3.2.2. AVAILABILITY OF ALTERNATIVE THERAPIES
3.2.3. HIGH COSTS OF SPECIALTY PRODUCTS AND A COMPLEX REIMBURSEMENT LANDSCAPE
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.2.1. EMERGING STEM CELL THERAPY IN THE TREATMENT OF DRY EYE DISEASE
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.4.1. GROWTH PROSPECT MAPPING FOR NORTH AMERICA DRY EYE DISEASE MARKET
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. MANUFACTURING
4.7.3. DISTRIBUTORS
4.7.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DOSAGE
7.1. EYE DROPS
7.2. EYE SOLUTIONS
7.3. OINTMENTS
7.4. GELS
7.5. CAPSULES & TABLETS
8. MARKET BY DISTRIBUTION CHANNEL
8.1. HOSPITAL PHARMACIES
8.2. INDEPENDENT PHARMACIES AND DRUG STORES
8.3. ONLINE PHARMACIES/STORES
9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. NORTH AMERICA DRY EYE DISEASE MARKET DRIVERS
9.1.3. NORTH AMERICA DRY EYE DISEASE MARKET CHALLENGES
9.1.4. NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
9.1.5. KEY PLAYERS IN NORTH AMERICA DRY EYE DISEASE MARKET
9.1.6. COUNTRY ANALYSIS
9.1.6.1. UNITED STATES
9.1.6.1.1. UNITED STATES DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9.1.6.2. CANADA
9.1.6.2.1. CANADA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. ALCON
10.2.1.1. COMPANY OVERVIEW
10.2.1.2. PRODUCT LIST
10.2.1.3. STRENGTHS & CHALLENGES
10.2.2. ALLERGAN PLC (ACQUIRED BY ABBVIE)
10.2.2.1. COMPANY OVERVIEW
10.2.2.2. PRODUCT LIST
10.2.2.3. STRENGTHS & CHALLENGES
10.2.3. BAUSCH HEALTH COMPANIES INC
10.2.3.1. COMPANY OVERVIEW
10.2.3.2. PRODUCT LIST
10.2.3.3. STRENGTHS & CHALLENGES
10.2.4. JOHNSON & JOHNSON
10.2.4.1. COMPANY OVERVIEW
10.2.4.2. PRODUCT LIST
10.2.4.3. STRENGTHS & CHALLENGES
10.2.5. AFT PHARMACEUTICALS
10.2.5.1. COMPANY OVERVIEW
10.2.5.2. PRODUCT LIST
10.2.5.3. STRENGTHS & CHALLENGES
10.2.6. LUMENIS
10.2.6.1. COMPANY OVERVIEW
10.2.6.2. PRODUCT LIST
10.2.6.3. STRENGTHS & CHALLENGES
10.2.7. NOVALIQ GMBH
10.2.7.1. COMPANY OVERVIEW
10.2.7.2. PRODUCT LIST
10.2.7.3. STRENGTHS & CHALLENGES
10.2.8. OASIS MEDICAL
10.2.8.1. COMPANY OVERVIEW
10.2.8.2. PRODUCTS LIST
10.2.8.3. STRENGTHS & CHALLENGES
10.2.9. OTSUKA PHARMACEUTICAL CO LTD
10.2.9.1. COMPANY OVERVIEW
10.2.9.2. PRODUCT LIST
10.2.9.3. STRENGTHS & CHALLENGES
10.2.10. SANTEN PHARMACEUTICAL CO LTD
10.2.10.1. COMPANY OVERVIEW
10.2.10.2. PRODUCTS LIST
10.2.10.3. STRENGTHS & CHALLENGES
10.2.11. NOVARTIS AG
10.2.11.1. COMPANY OVERVIEW
10.2.11.2. PRODUCT LIST
10.2.11.3. STRENGTHS & CHALLENGES
10.2.12. SENTISS PHARMA PRIVATE LIMITED
10.2.12.1. COMPANY OVERVIEW
10.2.12.2. PRODUCTS LIST
10.2.12.3. STRENGTHS & CHALLENGES
10.2.13. TEVA PHARMACEUTICAL INDUSTRIES LTD
10.2.13.1. COMPANY OVERVIEW
10.2.13.2. PRODUCT LIST
10.2.13.3. STRENGTHS & CHALLENGES
10.2.14. SUN PHARMACEUTICAL INDUSTRIES LTD
10.2.14.1. COMPANY OVERVIEW
10.2.14.2. PRODUCT LIST
10.2.14.3. STRENGTHS & CHALLENGES
10.2.15. VISUFARMA
10.2.15.1. COMPANY OVERVIEW
10.2.15.2. PRODUCT LIST
10.2.15.3. STRENGTHS & CHALLENGES